April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intracellular localisation of human bestrophin in neuronal cells after transduction with an AAV2.CBA.hBEST1.WPRE vector
Author Affiliations & Notes
  • Shaun Wood
    Nuffield Laboratory of Ophthalmology, The University of Oxford, Oxford, United Kingdom
  • Michelle McClements
    Nuffield Laboratory of Ophthalmology, The University of Oxford, Oxford, United Kingdom
  • Robert E MacLaren
    Nuffield Laboratory of Ophthalmology, The University of Oxford, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships Shaun Wood, None; Michelle McClements, None; Robert MacLaren, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 384. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shaun Wood, Michelle McClements, Robert E MacLaren; Intracellular localisation of human bestrophin in neuronal cells after transduction with an AAV2.CBA.hBEST1.WPRE vector. Invest. Ophthalmol. Vis. Sci. 2014;55(13):384.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Mutations in the human BEST1 gene are responsible for a wide-range of retinal disorders broadly classified as Bestrophinopathies. The BEST1 protein is known to be expressed in the retinal pigment epithelium (RPE) where it localises to the membrane and acts as a Cl- channel. Delivery of hBEST1 to the RPE cells of the retina is a potential treatment option for patients with bestrophinopathy. Potential expression of BEST1 in other cell types of the retina however could be problematic, particularly in neurons where a channel protein could influence function or even trigger apoptosis. We therefore sought to identify the membrane localisation patern of hBEST1 when expressed ectopically from a powerful expression cassette used in a current clinical trial - AAV2 CAG.hBEST1.WPRE.pA in HEK293T cells in vitro.

Methods: Human BEST1, driven by the ubiquitous CAG promoter and with a downstream WPRE sequence, was packaged into AAV2 capsids and used for in vitro assessment in HEK 293T cells. Commercially available anti-BEST1 antibodies were tested for their ability to detect the human BEST1 protein via western blot. Immunocytochemical (ICC) staining was also performed to determine localisation of BEST1 within the HEK293T cells. Histological sections of wild-type mouse eyes were prepared and immunostained to determine native BEST1 expression throughout the different layers of the retina using the human-specific antibody.

Results: Western blots using transfected and transduced HEK293T lysates detected large amounts of hBEST1 protein at the predicted size of 67 kDa, indicating successful overexpression from the plasmid and AAV2 vectors respectively. ICC on the HEK293T cells however showed BEST1 expression in the cytosol with little localisation at the cell membranes. Staining of the wild type mouse eyes indicated some expression of BEST1 in the RPE confirming broad species specificity of the antibodies.

Conclusions: An AAV2 vector carrying CAG.hBEST1 has been generated and successfully used to express hBEST1 in vitro. Although initial tests suggest that the localisation of the protein would render it non-functional in this cell line, further functional tests will be required to confirm this.

Keywords: 538 gene transfer/gene therapy • 701 retinal pigment epithelium • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×